October 10, 2014
PHILADELPHIA — Data presented at IDWeek 2014 indicate that the 13-valent pneumococcal conjugate vaccine has significantly reduced the number of antimicrobial-resistant invasive pneumococcal diseases since its introduction in 2010, achieving the Healthy People 2020 goal 9 years before the target year.
Researchers used data from ten Active Bacterial Core surveillance sites to assess the impact of PCV13 (Prevnar13, Pfizer) on antimicrobial-resistant invasive pneumococcal disease (IPD) among children aged younger than 5 years. Data were collected from 2005 to 2013. A bacterial isolate exhibiting intermediate or resistant patterns to one or more classes of antimicrobials (ie, penicillins, macrolides, cephalosporins and tetracyclines) was considered antimicrobial-resistant. Isolates resistant to three or more antimicrobial classes were considered multidrug-resistant.
From 2005 to 2009, prior to PCV13, there were 745 resistant cases of IPD. There were 378 resistant cases of IPD after the introduction of PCV13 from 2010 to 2013.
Overall incidence of antimicrobial-resistant IPD among children aged younger than 5 years decreased from 9.3 cases per 100,000 in 2009 to 3.5 per 100,000 in 2013.
PCV13, first available in 2010, reduced the incidence of all antimicrobial-resistant IPD by 62% from 2009 to 2013, according to researchers. Similarly, multidrug-resistant IPD decreased by 85%. Approximately 4,441 cases of antimicrobial-resistant IPD were prevented post-PCV13 from 2010 to 2013.
“Large decreases were seen in antimicrobial-resistant PCV13-only type disease, as well as multi-drug-resistant PCV13-only type disease. There is early evidence of a small increase in the rate of non-vaccine type, antimicrobial-resistant IPD,” Sara Tomczyk, of the CDC’s Respiratory Diseases Branch in Atlanta, said in a press conference.
During the conference, Tomczyk suggested that surveillance should continue to monitor new trends in antimicrobial resistance, particularly non-vaccine types and that more research on antimicrobial use is needed.
“To maintain low rates of antimicrobial resistance, in addition to appropriate antimicrobial use, we recommend sustained high use of PCV13 because we have demonstrated it as a
powerful tool against resistance,” Tomczyk said during the conference. — by Amanda Oldt
For more information:
Tomczyk S. Abstract 79. Presented at: ID Week 2014; Oct. 8-12; Philadelphia.
Disclosure: Some of the researchers report financial ties with Merck, Accelerate Diagnostics, Pfizer, and Sanofi-Pasteur.